Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs

Despite the significant achievements in chemotherapy, cancer remains one of the leading causes of death. Target therapy revolutionized this field, but efficiencies of target drugs show dramatic variation among individual patients. Personalization of target therapies remains, therefore, a challenge i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Marianna A. Zolotovskaia, Maxim I. Sorokin, Anna A. Emelianova, Nikolay M. Borisov, Denis V. Kuzmin, Pieter Borger, Andrew V. Garazha, Anton A. Buzdin
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019-01-01
Serija:Frontiers in Pharmacology
Teme:
cancer
DNA mutation
molecular pathways
biomarker
target drugs
tyrosine kinase inhibitors
Online pristup:https://www.frontiersin.org/article/10.3389/fphar.2019.00001/full
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items